EP
REPL icon

Eversept Partners’s Replimune Group REPL Stock Holding History

Eversept Partners’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,000
Closed -$398K – 143
2026
Q1 		$398K Buy
+52,000
New +$397K 0.02% 115

Other funds holding REPL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $80.9M AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Eversept Partners's REPL Position: Q2 2026 in Review

Eversept Partners increased its Replimune Group (REPL) stake by 76% in Q2 2026, buying an estimated $1.56M and bringing the position to 590,252 shares worth $6.53M. The position accounts for 0.34% of the portfolio, ranked #61.

Eversept Partners first reported a position in REPL in Q3 2025 and has held it in 3 quarters since. 199 funds tracked by Wall St. Rank hold REPL as of Q2 2026.

  • Eversept Partners held 590,252 shares of Replimune Group worth $6.53M as of Q2 2026.
  • Eversept Partners bought 255,391 Replimune Group shares in Q2 2026, an estimated $1.56M.
  • Replimune Group made up 0.34% of Eversept Partners's portfolio in Q2 2026, its #61 holding.
  • Eversept Partners first reported a position in Replimune Group in Q3 2025 and has held it in 3 quarters since.
  • 199 funds tracked by Wall St. Rank held Replimune Group as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.